The Cardiff-based family law firm was established in 1996 with co-founder Mel Hamer with an appetite for sustained growth

A leading family law firm is celebrating 30 years as it continues to expand. Cardiff-based Wendy Hopkins Family Law Practice was established as the first specialist family law firm in Wales, and one of the first in the UK, in May 1996.

It launched with just two partners, one paralegal and three secretaries – drawn from the family law team at the Cardiff office of Eversheds (now Eversheds Sutherland). The firm was then known as Wendy Hopkins & Co.

Melanie Hamer, one of its original co-founders, along with the late Wendy Hopkins, is still with the firm today.

Director Ms Hamer said: “I was just 30 years old, newly married and was presented with this enormous opportunity by Eversheds. It was a risk, as with all new firms, but I felt at the time it was a manageable risk. I decided that I would give it three years and if it did not work, I could always get out and get a job. I had to borrow just £35,000 from the bank to co-finance the firm at the beginning.

Fast forward 30 years and the firm’s revenues have grown from £220,000 gross in its first year of trading to nearly £3m in its last financial year. The team has increased from six to 22.

READ MORE: The knowhow built up in Wales’ contact centre sector is an asset worth redirectingREAD MORE: Expansion for community-owned west Wales seaweed and shellfish farming venture

Ms Hamer said: “We started on client number 100 because we did not want anybody to be client number 1 and for the outside world to think we didn’t have any clients. We are now on client number 13,365 meaning that over the last thirty years we have serviced 13,265 clients.

“I can’t quite believe my luck. I never set out with a big ambition or business plan to be one of the best family law firms in the UK. In the early days, I just hoped to make enough money to pay my mortgage.

“The success of the firm has exceeded all my wildest expectations, and I have great faith in my team that it will continue the great reputation of the firm for years to come, and we shall continue to punch above our weight, often attracting work from London as well as closer to Wales.”

The firm’s clients include high net worth individuals, celebrities, sports personalities and business owners. It recently acted on a case worth £77m.

The firms’ ownership structure also evolved over the years. At launch the only option available was to be a partnership. As soon as it able to it became a limited liability partnership (LLP) and latterly a limited company. It has expanded from two partners to five directors and three shareholders. Originally operating out of rented office space at 26 Windsor Place, it now own occupies 10,000 sq ft of owned space at the 12 and 13 Windsor Place.

On the success of the firm over the last 30 years, Ms Hamer said: “It is a combination of matters. We employ clever and conscientious people, and we make sure we look after them. From day one we have grown organically by taking lawyers on as paralegals and then in due course promoting them to trainee solicitor and then solicitor etc. Indeed, one of my shareholders and directors started as my trainee in the year 2000.

” Another director and shareholder started as a paralegal in 2011. The firm genuinely feels like a part of my extended family, and I care deeply about them all. I was also blessed with being in partnership until two years ago with one of my best friends, Thea Hughes, who retired in May 2024.

Ms Hamer, 60, says she no plans to retire. She added: “I still love my job, and I still feel that I do a good job, so as long as I continue to tick those boxes, then I see no reason to retire.”

NEW YORK — Celcuity Inc. shares surged more than 13.8 percent to $143 in early trading Monday, May 4, 2026, after the clinical-stage oncology company announced that its Phase 3 VIKTORIA-1 trial met the primary endpoint with clinically meaningful improvement in progression-free survival for patients with PIK3CA-mutant advanced breast cancer. The positive topline results for gedatolisib sent the biotech stock to new highs and reignited investor enthusiasm for the company’s targeted therapy pipeline just weeks before a potential FDA submission.

Celcuity reported that both the gedatolisib triplet and doublet regimens demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to the control arm in the PIK3CA mutant cohort. The data, released late Friday, May 1, triggered a sharp after-hours rally that carried into Monday’s session. The company said the results support advancing toward a supplemental New Drug Application (sNDA) filing with the FDA, with a potential PDUFA target in July 2026.

The VIKTORIA-1 trial evaluated gedatolisib in combination with standard therapies for HR+/HER2- advanced breast cancer patients who had progressed after prior CDK4/6 inhibitor treatment. Gedatolisib, a first-in-class PI3K/mTOR inhibitor, targets a pathway frequently altered in breast cancer. Positive data in the PIK3CA mutant population — a subgroup with historically poorer outcomes — positions the drug as a potential new standard of care option in a market estimated to exceed $5 billion annually at peak.

Celcuity CEO Brian Sullivan called the results a “transformational milestone” for the company and patients. “These data demonstrate gedatolisib’s potential to meaningfully improve outcomes in a population with significant unmet need,” Sullivan said in the company’s release. The firm is now accelerating commercial launch preparations while advancing additional indications for the drug across multiple solid tumors.

The stock reaction reflects high expectations. Celcuity has been on many biotech investors’ radars due to gedatolisib’s profile and its near-term regulatory timeline. Analysts have issued bullish price targets, with some projecting peak annual revenue exceeding $2.5 billion if the drug secures approval across multiple lines of therapy. Monday’s surge pushed the company’s market capitalization well above $6 billion.

The trial success comes at a pivotal time for Celcuity. The company has been advancing its precision medicine platform, which uses live tumor cell testing to identify patients most likely to benefit from targeted therapies. Gedatolisib represents the lead asset in this approach, and positive Phase 3 data significantly de-risks the program while strengthening its position ahead of potential partnership or commercialization discussions.

Broader market context amplified the move. Biotech stocks have shown renewed strength in 2026 amid improving regulatory sentiment and investor appetite for late-stage assets with clear paths to approval. Celcuity’s data stands out for its statistical robustness and clinical relevance in a competitive breast cancer landscape dominated by CDK4/6 inhibitors and antibody-drug conjugates.

Analysts reacted swiftly. Citizens initiated coverage with a Market Outperform rating and $150 price target earlier in the week, citing the drug’s potential. Other firms have highlighted the July 2026 PDUFA timeline as a key catalyst. While some caution remains around commercial execution and competition, the overall sentiment has turned increasingly bullish following the topline readout.

For patients and physicians, the results offer hope for better options in later-line HR+/HER2- breast cancer. PIK3CA mutations occur in approximately 40 percent of cases, and effective targeted therapies have been limited. Gedatolisib’s mechanism and tolerability profile could fill an important gap if approved.

Celcuity has cash reserves to support operations through key milestones, including potential approval and launch. The company continues enrolling patients in additional trials exploring gedatolisib in other settings and tumor types, positioning it for potential label expansion in the years ahead.

As trading continued Monday morning, volume remained elevated and the stock held near session highs. The move underscores the biotech sector’s sensitivity to clinical data, where positive Phase 3 readouts can drive outsized gains even in a broader market environment focused on macro signals and Federal Reserve policy.

Looking forward, all eyes are on the full dataset presentation at an upcoming medical meeting and the company’s regulatory strategy. If the FDA accepts the filing with priority review, approval could come as early as late 2026, setting the stage for Celcuity’s transition from clinical developer to commercial-stage oncology company.

The surge in Celcuity stock serves as a reminder of the high-reward potential in targeted oncology. For investors who backed the company through its development phase, Monday’s gains validate the long-term bet on gedatolisib. As the story unfolds, the biotech community will watch closely to see whether this positive momentum translates into sustained value creation in the competitive breast cancer market.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Short position through short-selling of the stock, or purchase of put options or similar derivatives in CWT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

DISCLAIMER: This analysis is not advice to buy or sell this or any stock; it is just pointing out an objective observation of unique patterns that developed from our research. Factual material is obtained from sources believed to be reliable, but the poster is not responsible for any errors or omissions, or for the results of actions taken based on information contained herein. Nothing herein should be construed as an offer to buy or sell securities or to give individual investment advice.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.